Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Virologic Efficacy of REGN-COV2 in COVID-19 Outpatients
NCT04666441Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Dec 2020
- Primary completion
- Mar 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of casirivimab, imdevimab in coronavirus disease 2019 (COVID-19), sponsored by Regeneron Pharmaceuticals. Started Dec 2020; status: completed.
02
Drugs
casirivimabimdevimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04666441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04666441.